ライフサイエンスコーパス: JDM

1 JDM patients can be monitored with noninvasive P-31 MRS

2 JDM patients with anti-p140 antibodies and tumour necros

3 scle biopsies of four untreated DQA1*0501(+) JDM children with profiles from children with a known ne

4 with this, peripheral blood Tregs of active JDM patients were less capable of suppressing effector T

5 Free Mg(2+) levels were normal in DM and JDM myopathic muscles at rest, but were significantly lo

6 Mg-ATP levels in DM and JDM myopathic muscles were at least 37% lower than those

7 with weakness and fatigue observed in DM and JDM patients.

8 recovery (P < 0.029 and P < 0.005 for DM and JDM, respectively).

9 hallenges of studying a rare disease such as JDM have been overcome by several collaborative studies

10 nt with the weakness and fatigue reported by JDM patients.

11 seases, especially juvenile dermatomyositis (JDM) and systemic sclerosis; however, little is known ab

12 Juvenile dermatomyositis (JDM) is a multisystem autoimmune disease that at times r

13 Juvenile dermatomyositis (JDM) is an immune-mediated inflammatory disease affectin

14 e 1 month prior to juvenile dermatomyositis (JDM) may trigger the onset of disease.

15 Juvenile dermatomyositis (JDM), the most common pediatric inflammatory myopathy, i

16 in high levels in juvenile dermatomyositis (JDM), which may account the frequency of autoantibodies

17 he many aspects of juvenile dermatomyositis (JDM).

18 ich appear to be risk factors for developing JDM or for developing complications such as calcinosis,

19 MRI is useful in diagnosing JDM and may be used as a disease assessment tool.

20 sphorylation in the mitochondria of diseased JDM muscles.

21 henotype and function of Tregs in blood from JDM patients by flow cytometry and in vitro suppression

22 33.75 +/- 8.4 IFN-gamma-producing cells from JDM cells vs 5.0 +/- 1.25 from maternal cells), and that

23 These include new autoantibodies in JDM (p140, which appears to have an association with cal

24 Both in JDM and Duchenne's muscular dystrophy the proportion of

25 ence of maternally derived chimeric cells in JDM patients and healthy controls, and assessed immunolo

26 nization for classifying inactive disease in JDM have practical applicability to the current clinical

27 arly half (47%) of the dysregulated genes in JDM were associated with the immune response.

28 One of the latest to be identified in JDM targets the protein NXP-2 and is associated with an

29 o an infectious process may be implicated in JDM disease pathogenesis.

30 rnational definition of disease remission in JDM has been agreed, which will aid disease assessment i

31 Falpha isolated from the calcific tissues in JDM have also been implicated in the pathologic process.

32 , and suggest a regulatory role for Tregs in JDM inflammation.

33 A role for Tregs in JDM pathogenesis has not yet been established.

34 Interestingly, JDM is not a self-remitting disease, suggesting that the

35 tegrate across judgment and decision making (JDM) phenomena.

36 ), juvenile-onset, type 1 diabetes mellitus (JDM), Down syndrome (DS)/trisomy 21, and the carrier sta

37 "Mindful" JDM research leverages our knowledge about psychological

38 all, Treg percentages in peripheral blood of JDM patients were similar compared to both control group

39 ective in increasing the aerobic capacity of JDM patients in remission.

40 er 16.8 years of symptom onset, over half of JDM patients still have active disease.

41 ta regarding extramuscular manifestations of JDM should allow researchers to continue elucidating the

42 or caretakers of children within 6 months of JDM diagnosis were interviewed by the registry study nur

43 d function in peripheral blood and muscle of JDM patients.

44 Mean ATP and PCr levels in the muscles of JDM patients were 35-40% below the normal control values

45 ll activation in vitro, compared to Tregs of JDM in clinical remission.

46 ad no muscle weakness (amyopathic variant of JDM).

47 t definite symptom (rash and/or weakness) of JDM are supported by immunologic data that suggest that

48 Muscle biopsies of new onset JDM patients showed increased infiltration of numbers of

49 finite/probable JDM (n = 234, 82%), possible JDM (n = 43, 15%), or rash only (n = 9, 3%).

50 Diagnoses were as follows: definite/probable JDM (n = 234, 82%), possible JDM (n = 43, 15%), or rash

51 imeric T cells are responsive to the host's (JDM childs') lymphocytes (33.75 +/- 8.4 IFN-gamma-produc

52 This study provides evidence that JDM affects young children.

53 edical records were reviewed, confirming the JDM diagnosis.

54 hat chimeric cells play a direct role in the JDM disease process and that the mother's HLA genotype f

55 The presence of chimerism in the JDM patients, their healthy siblings, and unaffected con

56 cells in muscles were increased compared to JDM peripheral blood.

57 d chimeric cells more often in children with JDM (60 of 72) than in their unaffected siblings (11 of

58 addition in the evaluation of children with JDM.

59 Thirteen patients with JDM (ages 4-16 years) were studied.

60 eve its primary end point, but patients with JDM did show good improvement in disease activity.

61 ave been found in the serum of patients with JDM.

62 tients with DM and 10 juvenile patients with JDM.